Search results
Showing 361 to 367 of 367 results for heart failure
More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.
Patients with rare blood disorders to receive new treatment option, says NICE
In final guidance published today (20 May 2021), NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria (PNH). Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome (aHUS).
NICE draft guidance recommends new treatment for chronic heart failure
Up to 150,000 people in England with a type of chronic heart failure are set to benefit from a new treatment following its approval by NICE.
People at risk of severe COVID-19 to have access to antiviral Paxlovid
A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be eligible for Paxlovid if they test positive.
NICE has approved mavacamten, the first treatment that specifically targets a heart condition called obstructive hypertrophic cardiomyopathy (HCM). It means around 7,000 people will now be able to access the treatment on the NHS.
NICE recommends life-changing gene therapy for children with ultra-rare genetic disorder
The first and currently only gene therapy for children with an ultra-rare genetic disorder has been recommended by NICE.
Extracorporeal membrane oxygenation for severe acute respiratory failure in adults (IPG391)
Evidence-based recommendations on extracorporeal membrane oxygenation for severe acute respiratory failure in adults. This involves using a tube to carry blood from the right side of the heart and then pump it through an artificial lung where it picks up oxygen.
View recommendations for IPG391Show all sections
Sections for IPG391